Steve Krognes has served as a member of Guardant Health’s Board of Directors since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector. Before joining the Board, Mr. Krognes was Chief Financial Officer at Denali Therapeutics Inc. from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche Holding AG. From July 2002 to December 2003, Mr. Krognes served as Director of M&A at Danske Bank based in Norway.
Mr. Krognes currently serves as a member of the Board of Directors at Denali Therapeutics Inc., Gritstone bio, Inc., argenx SE and ClavystBio, and previously served on the Board of Directors at Corvus Pharmaceuticals, Inc. from January 2016 to March 2021 and RLS Global AB from January 2016 to January 2023. He received a Master of Business Administration degree from Harvard Business School and a Bachelor of Science degree in economics from The Wharton School of the University of Pennsylvania.
- Chair of the Audit Committee